FDA APPROVES EMPAGLIFLOZIN TO REDUCE CARDIOVASCULAR
DEATH IN ADULTS WITH TYPE 2 DIABETES
The U.S. Food and Drug Administration approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.